The unit develops phage-derived antibacterial protein therapeutics and bacterial viruses (bacteriophages or phages) to kill pathogens infecting humans or animals which are resistant to antibiotics.
Antimicrobial resistance (AMR) is a global threat to human and animal health, posing a massive economic and social burden on society. The overuse and misuse of antibiotics is one of the main drivers of AMR as resistance factors can spread rapidly from soil bacteria or animal pathogens to those that cause diseases in humans. Due to high R&D costs, companies have abandoned antibiotic development programs and thus, alternatives are urgently needed.
Bacteriophages present an effective alternative to combat AMR bacteria. Phages can be used for treatment but also for the prevention of infections.